What You’ll Learn
Discover the breakthrough that brought the first armored CAR T to market and the trends shaping what comes next.
- The first armored CAR T is now approved. RIMQARTO® marks a major milestone for next-generation cell therapy, reaching the market more than 15 years after the first armored CAR T entered the clinic.
- 1 in 5 CAR therapies are now armored. Armored CARs account for 20.9% of the current CAR therapy landscape, highlighting growing industry investment in enhanced cell engineering strategies.
- The next wave is already taking shape. Nearly 60% of armored CAR therapies remain in preclinical development, signaling a substantial pipeline of future candidates.
You May Also Be Interested In…
Learn More About Cell Therapy
What is Beacon Cell Therapy?
- The Most Comprehensive Way to Search the Cell Therapy Development Landscape: Unique search ontologies based on Cell Therapy drug and trial characteristics
- Market Leading Approach to Cell Therapy Preclinical & Clinical Data Curation: Manual curation of key Cell Therapy research and development data points by Cell Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cell Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
